Trial Profile
A Phase 2 Multi-center, Randomized, Double Blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Jul 2019
Price :
$35
*
At a glance
- Drugs Edonerpic (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Sponsors Toyama Chemical
- 08 Jul 2019 Results published in the JAMA Neurology
- 20 Jul 2017 Results presented at the Alzheimer's Association International Conference 2017
- 19 Jul 2017 Results published in a FUJIFILM Corporation Media Release.